Amgen Korea
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Satellite Symposium
How to Use PCSK9 Inhibitor for Secondary Prevention After ACS
Organized by CVRF and Supported by Educational Grant from Amgen Korea
Friday, April 23
4:55 PM ~ 5:57 PM * Korea Standard Time (UTC/GMT +9:00)
Live Theater (Channel 2)
Moderator(s): Duk-Woo Park
Panelist(s): Do-Yoon Kang, Osung Kwon
| 4:55 PM | Recent Update in Lipid Management for ACS Patients  Lecturer: Hyunjong Lee |
| 5:10 PM | Patient Outcomes in Long-Term LDL-C Management: Role of Imaging, Protocols and Guidelines Lecturer: Yoshiyasu Minami |
| 5:25 PM | PCSK9 in Patients with Recent ACS Lecturer: Yi Zhang |
| 5:40 PM | Panel Discussion |
Training Course
The PCSK9 Inhibitor: for Whom, When and Why?
Organized by CVRF and Supported by Educational Grant from Amgen Korea
Wednesday, April 21 ~ Saturday, April 24
Moderator(s): Jung-Sun Kim
| The Earlier, The Better' Strategy with Evolocumab in ACS Within 1 Year Lecturer: Donggyu Moon |
| Discussion |